Journal of Allergy & Therapy

Bisbenzylisoquinoline alkaloids: New perspectives on anti-allergic drug development

7^th International Conference on Allergy, Asthma and Clinical Immunology

September 14-15, 2016 Amsterdam, Netherlands

Jaime Ribeiro Filho

Instituto Oswaldo Cruz, Brazil

Posters & Accepted Abstracts: J Allergy Ther

Abstract:

Allergic diseases are major public health problem worldwide. Allergic asthma is a chronic inflammatory airway disease, characterized by intense eosinophil recruitment and activation and airway hyper-responsiveness (AHR). The anti-allergic therapy includes the use of drugs that cause significant side effects or are not effective under specific conditions, justifying the search for novel, safe and effective drugs. Bisbenzylisoquinoline alkaloids (BBA) are known for their significant biological effects on inflammation and allergy and recent findings placed BBA as inhibitors of calcium influx in many cell types. Our research group have demonstrated that BBA such as warifteine and curine present significant anti-inflammatory and antiallergic properties in different models, including: Inhibition of eosinophil recruitment and activation; inhibition of mast cell dependent responses; modulation cytokine and lipid mediator production both in vivo and in vitro; protection against anaphylactic shock in mice; inhibition of mucus production and AHR development; inhibition of and modulation of B-cell functions. Our findings suggest that these effects are due to calcium influx inhibition, resulting in modulation of many steps of leukocyte activation and function. In conclusion, BBA exhibit anti-allergic effects in models of lung, skin and systemic allergy in the absence of significant toxicity and as such have the potential for anti-allergic drug development.

Biography :

Email: jaimeribeirofilho@gmail.com